Browsing: Viral > HIV / AIDS
In this World AIDS Day interview we speak to Richard Koup, who was recently an author on a study reporting a trispecific antibody able to target 99% of HIV strains.
To date there have only been a handful of Phase III efficacy trials for HIV vaccine candidates, which have had varied, and in some cases controversial, results. Here we review the history of HIV vaccine efficacy studies and look into the vaccine candidates closest to front-line use.
The FDA has approved Juluca®, the first two-drug regimen for maintenance treatment of HIV infection in adults, with the hope of presenting additional treatment options and lessening the burden on HIV-infected adults.
Scientists have explored how the viral genome affects the infectious potency of HIV; discovering that viruses have likely evolved to remove CG dinucleotides in order to avoid surveillance to mammalian defence mechanisms.
Results from the Positive Perspectives global survey have been reported at the recent EACS conference, providing insights into the attitudes of HIV patients towards treatment, healthcare and stigma.
Despite significant advances in the treatment of human immunodeficiency virus (HIV), there remain challenges. This review highlights recent advances in the application of nanotechnology to drug delivery, specifically with the purpose of improving HIV therapy.
Researchers have developed a novel compound, L-HIPPO, which can prevent viral budding in HIV-infected cells. It has been suggested this compound could supplement existing ‘kick and kill’ strategies, allowing complete eradication of HIV in the body.
A novel trispecific antibody has been developed by researchers from the NIH and Sanofi, demonstrating effectiveness against of 99% of HIV strains and protective immunity in non-human primates.